Publications
Read the latest research publications from Singapore's multiple myeloma specialists, covering treatment strategies, prognostic factors, and clinical trials.
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Please access the link: https://www.sciencedirect.com/science/article/abs/pii/S014521261300194X# (opens in new tab)
Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Please access the link: https://www.nature.com/articles/bcj201662 (opens in new tab)
Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.
Please access the link: https://www.sciencedirect.com/science/article/pii/S1658387618300335 (opens in new tab)
Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Please access the link: https://pubmed.ncbi.nlm.nih.gov/31171473/ (opens in new tab)
Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. Please access the link: https://pubmed.ncbi.nlm.nih.gov/32630644/ (opens in new tab)
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Please access the link: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34480015/ (opens in new tab)
Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
Please access the link: https://www.nature.com/articles/bmt201643 (opens in new tab)